Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Delayed Severe Hypersensitivity Reaction during $Genexol-PM^{(R)}$ Infusion

Genexol-$PM^{(R)}$ 항암치료 중 발생한 지연성 중증 과민성반응 1예

  • Kim, Hyun-Kyung (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Kim, Su-Woo (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Kang, Hye-Won (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Kwon, Kyoung-Joo (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Park, Hye-Sung (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Ryu, Yon-Ju (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Lee, Jin-Hwa (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Chun, Eun-Mi (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Cho, Young-Joo (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Chang, Jung-Hyun (Department of Internal Medicine, Ewha Womans University School of Medicine)
  • 김현경 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 김서우 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 강혜원 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 권경주 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 박혜성 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 류연주 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 이진화 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 천은미 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 조영주 (이화여자대학교 의학전문대학원 내과학교실) ;
  • 장중현 (이화여자대학교 의학전문대학원 내과학교실)
  • Received : 2009.12.17
  • Accepted : 2010.01.12
  • Published : 2010.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Although $Taxo^{(R)}$ is one of the most successful drugs in current cancer chemotherapy against solid tumors, a major problem is hypersensitivity reactions that arises as a consequence of activation of the complement (C) system, "C activation-related pseudo-allergy". Most severe hypersenstivity reactions occur within the first few minutes of $Taxo^{(R)}$ administration, usually after the first or second dose. Here we report a case of a severe hypersensitivity reaction in a 72-year-old man undergoing $Genexol-PM^{(R)}$ infusion. Hypotension and polymorphic pruritic skin rash appeared 2 hours after the start of $Genexol-PM^{(R)}$ infusion (with an appropriate premedication). Treating with methylprednisolone, epinephrine and inotropic agents, reduced the hypotension and the skin rash disappeared. We report this case with a review of the literature.

Keywords

References

  1. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004;90:304-5. https://doi.org/10.1038/sj.bjc.6601303
  2. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009;102:179-87. https://doi.org/10.1016/S1081-1206(10)60078-6
  3. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16. https://doi.org/10.1158/1078-0432.CCR-03-0655
  4. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-14. https://doi.org/10.1093/annonc/mdm374
  5. Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005;56:91-6. https://doi.org/10.1007/s00280-004-0924-9
  6. Ring J, Seifert J, Messmer K, Brendel W. Anaphylactoid reactions due to hydroxyethyl starch infusion. Eur Surg Res 1976;8:389-99. https://doi.org/10.1159/000127883
  7. Gilbar P, Ridge A. Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract 2002;8:81-7. https://doi.org/10.1191/1078155202jp096oa
  8. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216:106-21. https://doi.org/10.1016/j.tox.2005.07.023
  9. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721-35. https://doi.org/10.1016/S1567-5769(01)00006-6
  10. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37. https://doi.org/10.1016/j.ymthe.2005.09.014
  11. Szebeni J, Baranyi L, Savay S, Lutz HU, Jelezarova E. Bunger R, et al. The role of complement activation in hypersensitivity to PEGylated liposomal doxorubicin (Doxil). J Liposome Res 2000;10:467-81. https://doi.org/10.3109/08982100009031112
  12. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202. https://doi.org/10.1016/S0168-3659(01)00275-9

Cited by

  1. Overview of anaphylaxis in Korea: diagnosis and management vol.1, pp.3, 2013, https://doi.org/10.4168/aard.2013.1.3.181